Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (4975)	7/18/1998 2:41:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 7041

I read the patent and I though it refers to phentolamine mesylate and phentolamine hydrochloride. I didn't see phentolamine sulfate. The enforcability of the patent won't ever become an issue, because the patent "protects" an oral formulation for phentolamine for the sole purpose of "modulating the human sexual response". Since we already know that phentolamine does not "modulate the human sexual response", the patent is already worthless by definition. In other words, I could claim a mixture of seltzer water, lime juice and chocolate syrup for modulating the human sexual response, but a patent for this "ED medication" will get me just about as much as what a Zonagen shareholder is going to be getting soon. The patent office does not make any determination as to the efficacy of drugs - that's the job of the FDA. Zonagen is a fraud and a scam, and Joe Podolski is a filthy crook.